Search results
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).
We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.
It is important to avoid harming your vision, particularly if you have an inherited sight loss condition.
Vanessa is the General Counsel at the Alan Turing Institute, the UK’s national data science and artificial intelligence research institute.
With various events to choose from in 2026, these hugely popular events are back for another year! Round up your friends, family members and colleagues and join #TeamRetinaUK for a fun day out!
With various events to choose from in 2026, these hugely popular events are back for another year! Round up your friends, family members and colleagues and join #TeamRetinaUK for a fun day out in 2026.
Skydiving is an exhilarating experience, and you can do this while supporting our cause. Various dates and locations are available across the UK.
Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.
Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.
